All Articles

A trader can be right most of the time and still lose money. Another can be wrong more often than right and still grow an account steadily. The difference is not prediction. It is position sizing, risk control, and the maths behind risk to reward. If a trader wins 40% of trades but makes three times more on winners than they loses on losers, the account can grow. If another trader wins 70% of trades but keeps taking small profits and allows a few losses to become huge, the ac

A trader can follow a sound strategy in the morning and still make poor decisions by the afternoon. The market may not have changed much. The edge may still be there. What changed is the trader’s brain. Burnout in trading often hides behind normal-sounding habits. Watching one more candle. Checking one more timeframe. Staying exposed because “something might happen”. Over time, that constant pressure drains the mental systems needed for judgement, patience and self-control. T

Biotech investing is often a binary bet on clinical trials. However, BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) has fundamentally rewritten its story. Trading at $8.47 with a market capitalization of $2.16 billion, BCRX has successfully crossed the chasm from a cash-burning R&D shop to a profitable, self-sustaining rare disease powerhouse. For investors looking at the company today, the thesis has shifted from speculative pipe-dreams to core operational execution. Driven by

Mega-cap technology earnings are doing more than moving single stocks. They are setting the short-term tone for the whole risk market, from the Nasdaq and global tech funds to Bitcoin, Ethereum and retail sector positioning. The immediate link is clear enough. When the largest technology firms deliver reports that confirm demand for cloud computing, artificial intelligence infrastructure, digital advertising, semiconductors or consumer devices, tech indices tend to catch a bi

Barings Bank had survived wars, revolutions, market panics, and more than two centuries of financial upheaval. It financed governments, served aristocrats, and stood as one of Britain’s oldest merchant banks. Then, in 1995, it collapsed under the weight of one trader’s hidden losses in Singapore. The story of Nick Leeson is often told as the tale of a lone rogue operator. That is true, but incomplete. Leeson placed the bets. Leeson hid the losses. Leeson falsified the picture

Hedera is not a stock: HBAR is the native cryptoasset of the Hedera network. That distinction matters because HBAR trades 24/7, has different valuation drivers from an equity and can move sharply on liquidity, listings, token flows and sentiment. This trader-focused briefing reviews the latest reported developments available on 28 September 2026 and highlights the evidence, catalysts and risks worth monitoring. HBAR at a glance Reported spot-price area: approximately $0.093–$

Nvidia is still the stock at the centre of the AI trade. For traders, the opportunity is not just the headline growth — it is the gap between what Nvidia reports and what the market has already priced in. This practical update separates the numbers, catalysts and risks that matter most right now. The numbers traders need first Latest reported quarter: Q2 fiscal 2027, for the period ended 26 July 2026. Revenue: approximately $96.2 billion, reported as up 106% year over year. D

Most beginners add indicators because the chart feels unclear. Then the chart becomes even harder to read. Price action takes the opposite route: reduce the noise, study how price moves, and build decisions from candles, trends, and key zones. This guide explains a practical price action trading strategy from the ground up. It covers Japanese candlesticks, trend structure, support and resistance, institutional order flow, and a rules-based way to plan entries and exits on cle

A flower bulb once became so valuable that people spoke of it in the same breath as houses, land, silver cups, horses, and fortunes. In the Dutch Republic of the 1630s, a tulip was not just a tulip. It was a ticket to status, a private wager, a dinner-table boast, and, for a short feverish season, a way to become rich without lifting more than a quill. The rarest bulbs changed hands for sums that stunned even a wealthy trading nation. Some accounts claim a single bulb cost mo

A large trading loss does not only hit the account. It hits identity, confidence, and the nervous system. That is why revenge trading can feel so urgent. The trader knows the rules. They know the daily loss limit. They may even have the trading plan open beside them. Yet after one brutal stop-out, one failed breakout, or one fast liquidation, the next trade appears almost magnetic. The thought is simple: I just need to make it back. That thought is dangerous. Revenge trading

Markets are trading less on earnings stories and more on the next inflation decimal point. The global setup is simple but tense: investors want Federal Reserve rate cuts, inflation is not yet giving policymakers a clean win, and consumer spending still decides whether risk assets can hold their gains. That mix is creating sharp two-way moves across equities, credit, and currencies. Good data can be bad for stocks if it delays rate cuts. Softer spending can help bonds but hurt

The 1MDB scandal did not begin with a yacht, a Hollywood premiere, or a penthouse overlooking Manhattan. It began with an idea that sounded respectable: a Malaysian sovereign wealth fund built to invest in the country’s future. Within a few years, that fund had become the centre of one of the largest kleptocracy cases ever pursued by US authorities. Billions of dollars allegedly moved through shell companies, private banks, law firms, art dealers, luxury property markets, and